NCT06823349 Comparative Analysis of Analgesic Efficacy: by Single Shot Intrathecal Analgesia (SSSA) in Normal Labor
| NCT ID | NCT06823349 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Jehan George Sadek |
| Condition | Vaginal Delivery |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 90 participants in total. It began in 2025-02-01 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
the goal of this randomized control trial is to compare the effect of adding fentanyl v.s dexmedetomidine to bupivacaine in single shot spinal analgesia in achievement of analgesia by decreasing visual analogue scale, onset and increasing duration of analgesia in normal labor.
Eligibility Criteria
Inclusion Criteria: * ASA I-II. * Uncomplicated pregnancy. * At term \& singleton fetus. * Cervical dilatation \> 5cm * Cephalic presentations Exclusion Criteria: * Patient refusal. * Bleeding disorders and patients on anticoagulant drugs. * Infection at site of injection. * Spine deformity. * Allergy to any of study medications.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06823349 clinical trial?
This trial is open to female participants only, studying Vaginal Delivery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06823349 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06823349 currently recruiting?
Yes, NCT06823349 is actively recruiting participants. Contact the research team at jehan.younan1995@gmail.com for enrollment information.
Where is the NCT06823349 trial being conducted?
This trial is being conducted at Aswān, Egypt.
Who is sponsoring the NCT06823349 clinical trial?
NCT06823349 is sponsored by Jehan George Sadek. The trial plans to enroll 90 participants.